麻豆传媒

Jeffrey Shaman, PhD, MS, is the Chief Science Officer at Coriell Life Sciences where he oversees the company鈥檚 research, education, and clinical programs and leads efforts focused on bridging the gap between genetic science and clinical application.  Dr. Shaman brings years of experience in advising cross-functional teams together with his scholarship in genetics, pharmacology, stem cells, and clinical laboratory operations.  Along with the CEO, he forges strategic partnerships with worldwide companies, laboratories, academic institutions, public/private self-insured companies, and federal, state, and regional healthcare and employee systems.

Dr. Shaman supports a team of scientists dedicated to precision medicine and who actively research, publish, and present findings in top-tier peer-reviewed journals. He is passionate about educating people from all backgrounds about the power of genetics and pharmacogenomic testing that is integrated with patient health history and clinical decision-support to proactively promote better health.

Dr. Shaman holds a doctoral degree from The Johns Hopkins University School of Medicine in Pharmacology and Molecular Sciences, where his research centered on DNA, epigenetics, and nuclear structure and function. He earned his Master of Science degree from The University of Medicine and Dentistry of New Jersey in Cell & Developmental Biology.  Dr. Shaman held a faculty position at the University of Hawai鈥榠 Institute of Biogenesis Research before serving a fellowship at Harvard Medical School and implementing a translational research program at Beth Israel Deaconess Medical Center and the Bedford Stem Cell Research Foundation.

Triple board-certified in internal medicine, hematology and medical oncology, Dr. Mohamad Cherry is medical director of Hematology at Atlantic Health System Cancer Care. He joined Atlantic Hematology Oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center, bringing years of clinical knowledge and expertise.

With specialty training from some of the nation's most skilled clinicians, Dr. Cherry attained some of his clinical training at the leukemia department at MD Anderson and his fellowship in hematology/oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He performed two residencies - an internal medicine residency at Staten Island University Hospital and a laboratory medicine residency at the American University of Beirut Medical Center in Lebanon. Previously, Dr. Cherry attained his medical degree at Lebanese University and performed his internship at Sacre Coeur Hospital-Lebanese University. He also earned a master of science degree in clinical and translational research from University of Oklahoma College of Public Health.

Dr. Cherry remains on staff as clinical associate professor of hematology/oncology at University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He is also the director of its hematology/oncology fellowship program and co-chairs the Academy of Teaching Scholars Faculty Development, Education and Mentoring Committee. Other administrative roles include co-chair of the leukemia working group at the Sarah Cannon Research Institute Blood Cancer Consortium.

As a principal investigator of multiple clinical trials, Dr. Cherry has performed groundbreaking research in niche areas that include epigenetics and development of new therapeutics in relapsed and refractory blood cancers. He has developed teaching materials and book chapters, and has lectured both nationally and internationally.

Dr. Cherry continues to serves as a mentor and an advisor to fellows, residents and medical students. He contributes to continuing education, public health, and professional development, and has won awards and funding for both his research and his clinical pursuits.

Jim Carrington has come a long way since first stepping into a research laboratory as an undergraduate at the University of California, Riverside.

Research in the Carrington lab focuses on RNA-mediated regulation and silencing of genomes, genes and viruses. This lab focuses on the biogenesis, functions, and evolution of small RNA-directed silencing pathways in multicellular eukaryotes. Small RNA-based silencing serves a regulatory mechanism during growth and development and in response to stress. It also functions as a transposon and repeat silencing mechanism, and as an antiviral response in plants and some animals. The Carrington lab uses a combination of genetics, genomics, computation and other approaches to address fundamental mechanistic problems using model systems, but it also seeks to develop tools and approaches that have practical relevance in crop plants. The lab is particularly interested in the underlying mechanisms, including small RNA mechanisms, that govern plant-virus and plant-microbe interactions.

HTS studies in a variety of plants and other organisms have revealed the diversity of ancient and recently evolved miRNA genes, and vast arrays of siRNAs from long dsRNA. The systematic analysis of mutants with defects in miRNA and siRNA function revealed several distinct biogenesis pathways for each class, and target RNAs that are regulated by small RNA families. Distinct small RNA biogenesis and effector components are involved in transcriptional and post-transcriptional silencing systems in plants. They have explored biogenesis, effector and specificity mechanisms of miRNA, trans-acting siRNA (tasiRNA), antiviral siRNA, and other small RNA classes using Arabidopsis thaliana.